Taglich Brothers Comments on Trxade Group, Inc.’s Q1 2021 Earnings (NASDAQ:MEDS)


Share on StockTwits

Trxade Group, Inc. (NASDAQ:MEDS) – Equities research analysts at Taglich Brothers dropped their Q1 2021 earnings estimates for shares of Trxade Group in a report issued on Monday, April 5th. Taglich Brothers analyst H. Halpern now forecasts that the company will post earnings of ($0.03) per share for the quarter, down from their previous estimate of $0.03. Taglich Brothers also issued estimates for Trxade Group’s Q2 2021 earnings at ($0.02) EPS, Q3 2021 earnings at ($0.01) EPS, Q4 2021 earnings at ($0.01) EPS and FY2021 earnings at ($0.08) EPS.

Several other brokerages have also recently commented on MEDS. Zacks Investment Research cut shares of Trxade Group from a “hold” rating to a “sell” rating in a research report on Wednesday, March 31st. Maxim Group initiated coverage on shares of Trxade Group in a report on Friday, February 26th. They set a “buy” rating for the company. Finally, Colliers Securities restated a “buy” rating and set a $10.00 price target on shares of Trxade Group in a report on Tuesday, March 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Trxade Group presently has a consensus rating of “Buy” and an average target price of $10.81.

Shares of NASDAQ:MEDS opened at $5.00 on Thursday. Trxade Group has a 12 month low of $4.02 and a 12 month high of $8.25. The company has a debt-to-equity ratio of 0.02, a current ratio of 19.89 and a quick ratio of 16.81. The stock’s 50 day moving average price is $6.32 and its 200 day moving average price is $5.75. The stock has a market cap of $40.47 million, a price-to-earnings ratio of 166.67, a PEG ratio of 0.83 and a beta of 1.42.

Trxade Group (NASDAQ:MEDS) last posted its quarterly earnings data on Sunday, March 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.21). Trxade Group had a negative return on equity of 8.28% and a negative net margin of 4.28%.

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in Trxade Group by 28.9% during the third quarter. BlackRock Inc. now owns 10,426 shares of the company’s stock valued at $65,000 after acquiring an additional 2,336 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Trxade Group in the fourth quarter valued at approximately $212,000. Finally, National Asset Management Inc. acquired a new stake in shares of Trxade Group in the fourth quarter worth $454,000. Hedge funds and other institutional investors own 13.13% of the company’s stock.

Trxade Group Company Profile

Trxade Group, Inc, together with its subsidiaries, operates a business-to-business (B2B) web-based marketplace focused on the pharmaceutical industry in the United States. It operates through Trxade, Inc; Community Specialty Pharmacy, LLC; Integra Pharma, LLC; and Other segments. The company operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services.

Recommended Story: What is a good rate of return for a mutual fund?

Earnings History and Estimates for Trxade Group (NASDAQ:MEDS)

Receive News & Ratings for Trxade Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trxade Group and related companies with MarketBeat.com's FREE daily email newsletter.